Adding to a previous deal on dermatological products, Swedish firm Karo Pharma has now acquired a focused intimate care and dermatology product portfolio from privately-held Danish firm LEO Pharma for 90 million euros ($99.8 million).

The portfolio consists of four anti-hemorrhoid products (Sheriproct, Doloproct, Neriproct and Ultraproct) and six dermatology products (Ultrabas, Ultralip, Ultraphil, Ultrasicc, Neribas and Ultralan).